Biology Reference
In-Depth Information
poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in
combination with temozolomide (TMZ) in patients with meta-
static malignant melanoma (MM).
J Clin Oncol
2006;24(18s):8013.
129. Bedikian AY, Papadopoulos NE, Kim KB, Hwu W-J, Homsi J,
Glass MR, et al. A phase IB trial of intravenous INO-1001 plus
oral temozolomide in subjects with unresectable stage-III or IV
melanoma.
Cancer Invest
2009;27:756
144. Audeh M, Penson R, Friedlander M, Powell Bb-M, KM, Scott C,
Weitzel JC, J, et al. Phase II trial of the oral PARP inhibitor ola-
parib (AZD2281) in BRCA-deficient advanced ovarian cancer.
J Clin Oncol
2009; 27(15s): 5500.
145. Edwards S, Brough R, Lord C, Natrajan R, Vatcheva R, Levine D,
et al. Resistance to therapy caused by intragenic deletion in
BRCA2.
Nature
2008;451:1111
63.
130. Rajan A, Carter CA, Gutierrez M, Kummar S, Yancey MA, Ji JP,
et al. A phase I combination study of olaparib (AZD2281; KU-
0059436) and cisplatin plus gemcitabine in adults with solid
tumors.
J Thorac Oncol
2009;4(9):S598
e
5.
146. Sakai W, Swisher E, Karlan B, Agarwal M, Higgins J, Friedman C,
et al. Secondary mutations as a mechanism of cisplatin resistance
in BRCA2-mutated cancers.
Nature
2008;451:1116
e
20.
147. Ashworth A. What has and does DNA repair biology tell us?
Ann
Oncol
2010;21(Suppl. 4). Abstract 41N.
148. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene
expression profiles of BRCA1-linked, BRCA2-linked,
e
9.
131. Rajan A, Gutierrez M, Kummar S, Yancey M, Ji J, Zhang Y, et al.
A phase I combination study of Azd2281 and cisplatin plus
gemcitabine in adults with solid tumors.
Ann Oncol
2009;20:42
e
3.
132. Kummar S, Ji J, Zhang Y, Simmons D, Kinders R, Gutierrez ME,
et al. A phase I combination sudy of Abt-888 and topotecan
hydrochloride in adults with refractory solid tumors and
lymphomas.
Ann Oncol
2009;20:42
e
and
1000.
149. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T,
Fountzilas E, Francoeur N, et al. Gene expression profile of
BRCAness that correlates with responsiveness to chemotherapy
and with outcome in patients with epithelial ovarian cancer.
J Clin Oncol
2010;28:3555
sporadic ovarian cancers.
J Natl Cancer Inst
2002;94(13):990
e
3.
133. Mahany J, Lewis N, Heath E, LoRusso P, Mita M, Rodon J, et al.
A phase IB study evaluating BSI-201 in combination with
chemotherapy in subjects with advanced solid tumors.
J Clin
Oncol
2008;26:3579.
134. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D,
Monaghan G, et al. Efficacy of BSI-201, a poly (ADP-ribose) poly-
merase-1 (PARP1) inhibitor, in combination with gemcitabine/
carboplatin (G/C) in patients with metastatic triple-negative
breast cancer (TNBC): Results of a randomized phase II trial.
J Clin
Oncol
2009;27:3.
135. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG,
Lescoe MK, et al. Mutation in the DNA mismatch repair gene
homologue hMLH1 is associated with hereditary non-polyposis
colon cancer.
Nature
1994;368(6468):258
e
61.
150. Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC,
Powell SN. Utility of DNA repair protein foci for the detection of
putative BRCA1 pathway defects in breast cancer biopsies.
Mol
Cancer Res
2009;7(8):1304
e
9.
151. Asakawa H, Koizumi H, Koike A, Takahashi M, Wu W, Iwase H,
et al. Prediction of breast cancer sensitivity to neoadjuvant
chemotherapy based on status of DNA damage repair proteins.
Breast Cancer Res
12(2): 395
e
407.
152. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ,
Drew Y, Kyle S, et al. Development of a functional assay for
homologous recombination status in primary cultures of epithe-
lial ovarian tumor and correlation with sensitivity to poly(ADP-
ribose) polymerase inhibitors.
Clin Cancer Res
2010;16:2344
e
61.
136. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D,
Lopez E, et al. Specific killing of BRCA2-deficient tumours with
inhibitors of poly(ADP-ribose) polymerase.
Nature
2005;434(7035):
913
e
51.
153. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J,
et al. A marker of homologous recombination predicts pathologic
complete response to neoadjuvant chemotherapy in primary
breast cancer.
Clin Cancer Res
16(24): 6159
e
7.
137. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA,
Richardson TB, et al. Targeting the DNA repair defect in BRCA
mutant cells as a therapeutic strategy.
Nature
2005;434(7035):
917
e
68.
154. Gaymes TJ, Shall S, MacPherson LJ, Twine NA, Lea NC,
Farzaneh F, et al. Inhibitors of poly ADP-ribose polymerase
(PARP) induce apoptosis of myeloid leukemic cells: potential for
therapy of myeloid leukemia and myelodysplastic syndromes.
Haematologica
2009;94(5):638
e
21.
138. De Soto JA, Quick-Fountain R, Velikodvorskaya T, Fatima N. The
use of poly(ADP-ribose) polymerase (PARP1) inhibitors
(AG14361, AZD2281, ABT888) in combination with capecitabine,
5-fluorouracil, or paclitaxel in the treatment of hereditary and
sporadic breast and ovarian cancer.
J Clin Oncol
2010;(Suppl):28.
Abstract e13120.
139. Gallmeier E, Kern SE. Absence of specific cell killing of the
BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-
ribose) polymerase inhibition.
Cancer Biol Ther
2005;4(7):703
e
46.
155. Ahluwalia A, Hurteau JA, Bigsby RM, Nephew KP. DNA meth-
ylation in ovarian cancer. II. Expression of DNA methyl-
transferases in ovarian cancer cell lines and normal ovarian
epithelial cells.
Gynecol Oncol
2001;82(2):299
e
304.
156. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV,
Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-
BRCA pathway in cisplatin-sensitive ovarian tumors.
Nat Med
2003;9(5):568
e
6.
140. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S,
et al. Therapeutic potential of poly(ADP-ribose) polymerase
inhibitor AG014699 in human cancers with mutated or methyl-
ated BRCA1 or BRCA2.
J Natl Cancer Inst
2011;103(4):334
e
74.
157. Wang Z, Li M, Lu S, Zhang Y, Wang H. Promoter hyper-
methylation of FANCF plays an important role in the occurrence
of ovarian cancer through disrupting Fanconi anemia-BRCA
pathway.
Cancer Biol Ther
2006;5(3):256
e
46.
141. Gelmon KA, Hirte HW, Robidoux A, Tonkin KS, Tischkowitz M,
Swenerton K, et al. Can we define tumors that will respond to
PARP inhibitors? A phase II correlative study of olaparib in
advanced serous ovarian cancer and triple-negative breast cancer.
J Clin Oncol
2010;28(Suppl). Abstract 3002.
142. Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M, et al.
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA
mutation carriers.
N Engl J Med
2009;361(2):123
e
60.
158. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S,
et al. BRCA1 promoter region hypermethylation in ovarian
carcinoma: a population-based study.
Cancer Res
2000;60(19):
5329
e
33.
159. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X,
Lerma E, et al. Promoter hypermethylation and BRCA1 inacti-
vation in sporadic breast and ovarian tumors.
J Natl Cancer Inst
2000;92(7):564
e
34.
143. Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J,
et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-
deficient advanced breast cancer.
e
9.
160. Catteau A, Morris JR. BRCA1 methylation: a significant role in
tumour development?
Semin Cancer Biol
2002;12(5):359
e
J Clin Oncol
2009;27(18s).
CRA501.
e
71.